Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $7.66K | $39.9K | $215K | $74.6M | $97.9M | $34.2M | $6.81M | $3.92M | $622K |
| Revenue growth | — | — | 420.9% | 438.6% | 34579.9% | 31.3% | -65.0% | -80.1% | -42.5% | -84.1% |
| Gross profit | — | $7.36K | $30.5K | $103K | $58.0M | $86.3M | $28.7M | $2.63M | $2.92M | $400K |
| Gross margin | — | 96.1% | 76.5% | 47.7% | 77.7% | 88.2% | 84.0% | 38.6% | 74.5% | 64.3% |
| Operating income | -$1.69M | -$4.56M | -$6.12M | -$5.89M | $41.7M | $46.1M | -$27.0M | -$42.7M | -$40.1M | -$50.2M |
| Operating margin | — | -59567.6% | -15328.6% | -2741.6% | 55.9% | 47.1% | -78.8% | -626.9% | -1023.7% | -8058.8% |
| Net income | -$1.93M | -$6.96M | -$6.27M | -$6.20M | $42.5M | $36.7M | -$14.2M | -$35.3M | -$37.6M | -$46.9M |
| Net margin | — | -90827.9% | -15714.3% | -2882.0% | 57.0% | 37.5% | -41.6% | -518.7% | -961.4% | -7533.6% |
| EPS (diluted) | — | -$0.63 | -$0.50 | -$0.37 | $1.52 | $1.23 | -$0.45 | -$1.20 | -$37.22 | -$35.25 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.31M | -$3.21M | -$4.08M | -$5.53M | $28.2M | $41.1M | $6.57M | -$22.1M | -$29.2M | -$29.1M |
| Capital expenditures | $12.2K | $129K | $41.3K | $113K | $774K | $669K | $1.43M | $1.37M | $748K | $700K |
| Free cash flow | -$1.32M | -$3.34M | -$4.12M | -$5.64M | $27.4M | $40.4M | $5.14M | -$23.4M | -$29.9M | -$29.8M |
| Share buybacks | — | — | — | — | — | — | $14.2M | $1.36M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $999K | $3.53M | $950K | $893K | $43.0M | $88.6M | $23.0M | $14.9M | $2.94M | $11.9M |
| Total assets | $1.30M | $4.66M | $1.55M | $2.22M | $71.2M | $160M | $123M | $95.3M | $63.6M | $24.7M |
| Total liabilities | $4.29M | $812K | $2.61M | $478K | $4.54M | $25.6M | $8.57M | $9.31M | $9.69M | $4.11M |
| Long-term debt | — | — | $1.91M | — | — | — | — | — | — | — |
| Shareholders' equity | -$2.99M | $3.85M | -$1.06M | $1.74M | $66.7M | $134M | $115M | $85.6M | $53.9M | $20.6M |
| Retained earnings | -$5.46M | -$12.4M | -$18.7M | -$25.0M | $17.5M | $54.2M | $39.9M | $4.60M | -$33.5M | -$80.4M |
| Shares (wtd avg diluted) | 9.88M | 12.3M | 12.9M | 16.8M | 28.0M | 29.9M | 31.5M | 29.3M | 1.01M | 1.33M |
Every figure is extracted from Co-Diagnostics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.